1. Inicio
  2. Publicaciones
  3. (18)F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.

(18)F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Cordoba R
  • Sánchez-García J
  • Domingo-Domenech E
  • López Jiménez J
  • Martínez Pozo A
  • Carpio C
  • Bendaña Á
  • González AJ
  • Gómez Codina J
  • Navarro B
  • Rodríguez G
  • Naves A
  • Baeza L
  • Martín García-Sancho A

Unidades

Abstract

BACKGROUND: An accurate assessment of tumor viability after first-line treatment is critical for predicting treatment failure in peripheral T-cell lymphomas (PTCLs). (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) has been adopted as the preferred assessment method in clinical trials, but its impact in clinical practice should be examined. This study aims to determine the prognostic significance of(18)F-FDG-PET/CT for survival following first-line treatment in PTCL patients. RESEARCH DESIGN AND METHODS: Retrospective observational study including 175 patients diagnosed with PTCL between 2008-2013 in 13 Spanish sites. RESULTS: Fifty patients were evaluated with(18)F-FDG-PET/CT following first-line therapy: 58% were(18)F-FDG-PET/CT-negative and 42% were(18)F-FDG-PET/CT-positive. Disease progression occurred in 37.9% of(18)F-FDG-PET/CT-negative patients and in 80.9% of(18)F-FDG-PET/CT-positive patients (p = 0.0037). Median progression-free survival and overall survival were 67 and 74 months for(18)F-FDG-PET/CT-negative patients, and 5 (p < 0.0001) and 10 months (p < 0.0001), respectively, in(18)F-FDG-PET/CT-positive patients. After multivariate analysis, only B symptoms emerged as a negative predictive factor of complete response (RR 7.08; 95% CI 1.60-31.31; p = 0.001). CONCLUSIONS: (18)F-FDG-PET/CT identifies high-risk PTCL patients who will have poor prognosis and survival following first-line treatment. However, more research is needed to confirm the best treatment options for PTCL patients.

Datos de la publicación

ISSN/ISSNe:
1747-4086, 1747-4094

EXPERT REVIEW OF HEMATOLOGY  EXPERT REVIEWS

Tipo:
Article
Páginas:
1-6
PubMed:
38299464

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • 18F-FDG-PET/CT; Peripheral T-cell lymphoma; alternative therapies; first-line treatment; prognosis; response assessment

Compartir